Health Discovery Corporation Supports The Efforts Of New York Congressman Edolphus Towns And His Holding Of The Public Hearing On Prostate Cancer Screening
Health Discovery Corporation (OTCBB:
announced today that it delivered a letter of gratitude and support to
Congressman Edolphus Towns, Chairman of the House Committee on Oversight
and Government Reform for...
Health Discovery Corporation (OTCBB: HDVY) announced today that it delivered a letter of gratitude and support to Congressman Edolphus Towns, Chairman of the House Committee on Oversight and Government Reform for holding today, March 4, 2010, a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment.” “Congressman Towns’ public hearing is timely and appropriate, given the overwhelming data about the failures of the PSA for detecting clinically significant prostate cancer,” said Stephen D. Barnhill, Chairman and CEO of Health Discovery Corporation. “Given our pioneering work in molecular diagnostic testing for prostate cancer, Health Discovery Corporation naturally offered to Congressman Towns our gratitude, support and ourselves as a resource to him and his committee as he continues to explore this important issue,” said Dr. Barnhill. The full text of the letter is as follows: March 4, 2010 The Honorable Edolphus Towns, ChairmanHouse Committee on Oversight and Government Reform2157 Rayburn House Office BuildingWashington, DC 20515 Dear Chairman Towns, Thank you for your leadership on promoting awareness and research about prostate cancer. Indeed, it is our hope that your hearing, Prostate Cancer: New Questions About Screening and Treatment, will raise the level of understanding about prostate cancer among members and generate the kind of detailed examination that will help us advance research for testing and treatment for this terrible disease. As you well know, there is an estimated 192,280 new cases of prostate cancer in 2009 and some 27,360 deaths from the disease. Health Discovery Corporation’s new 4-gene molecular diagnostic test for prostate cancer has been shown to have a 90% Sensitivity (for finding clinically significant grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) was recently published in the peer-reviewed publication, UroToday International (August 2009). Health Discovery Corporation (HDC) shares your commitment to exploring solutions to prostate cancer. Indeed, HDC is a pioneer in developing sophisticated pattern recognition technology called “Support Vector Machine” (SVM) and has developed, and continues to develop, effective molecular diagnostic tests for cancer. Currently, we have 42 issued patents and 32 pending patents involving SVM technology.